Scholarlink

Introduction <p>Based on prospective trials’ result, it is unknown whether race/ethnicity affects the magnitude of cancer-specific survival differences after trimodal therapy (TMT) versus external beam radiation therapy alone (EBRT) for urothelial carcinoma for urinary bladder (UCUB). We addressed this knowledge gap.</p> Materials and methods <p>Within the Surveillance, Epidemiology, and End Results database (2004–2020), we identified patients with cT2-T4aN0M0 UCUB treated with either TMT or EBRT. We focused on the four most prevalent race/ethnicities: Caucasians, Hispanics, African American (AAs) and Asian/Pacific Islanders (APIs). Cumulative incidence plots and multivariable competing risks regression (CRR) models addressed cancer specific mortality (CSM) after additional adjustment for other-cause mortality (OCM) and standard covariates.</p> Results <p>Of 3249 patients, 2643 (81%) were Caucasians versus&#xa0;254 (8%) AAs versus 209 (7%) Hispanics versus 143 (4%) APIs. Compared to EBRT, TMT rates were higher in Caucasians (81%) and APIs (81%), lower in AAs (75%) and lowest in Hispanics (69%). In Caucasians, five-year CSM rates were 41.6% after TMT versus 49.0% after EBRT and TMT independently predicted lower CSM (HR: 0.70, p &lt; 0.001). In AAs, Hispanics and APIs, TMT did not predict CSM differences (p = 0.1, 0.2 and p = 0.06, respectively).</p> Conclusion <p>For Caucasians UCUB patients, TMT is strongly associated with significantly lower CSM. However, this observation cannot be generalized non-Caucasian subgroups, where TMT did not predict lower CSM relative to EBRT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of race/ethnicity on systemic chemotherapy in urothelial carcinoma patients exposed to radiotherapy

  • 期刊论文

  • 发表日期：

    2025年6月30日

查看全文
  • Mario de Angelis,
  • Carolin Siech,
  • Francesco Di Bello,
  • Natali Rodriguez Peñaranda,
  • Jordan A. Goyal,
  • Zhe Tian,
  • Nicola Longo,
  • Felix K. H. Chun,
  • Salvatore Micali,
  • Fred Saad,
  • Shahrokh F. Shariat,
  • Letizia Maria Ippolita Jannello,
  • Mattia Longoni,
  • Gennaro Musi,
  • Giorgio Gandaglia,
  • Marco Moschini,
  • Francesco Montorsi,
  • Alberto Briganti,
  • Pierre I. Karakiewicz

摘要

Introduction

Based on prospective trials’ result, it is unknown whether race/ethnicity affects the magnitude of cancer-specific survival differences after trimodal therapy (TMT) versus external beam radiation therapy alone (EBRT) for urothelial carcinoma for urinary bladder (UCUB). We addressed this knowledge gap.

Materials and methods

Within the Surveillance, Epidemiology, and End Results database (2004–2020), we identified patients with cT2-T4aN0M0 UCUB treated with either TMT or EBRT. We focused on the four most prevalent race/ethnicities: Caucasians, Hispanics, African American (AAs) and Asian/Pacific Islanders (APIs). Cumulative incidence plots and multivariable competing risks regression (CRR) models addressed cancer specific mortality (CSM) after additional adjustment for other-cause mortality (OCM) and standard covariates.

Results

Of 3249 patients, 2643 (81%) were Caucasians versus 254 (8%) AAs versus 209 (7%) Hispanics versus 143 (4%) APIs. Compared to EBRT, TMT rates were higher in Caucasians (81%) and APIs (81%), lower in AAs (75%) and lowest in Hispanics (69%). In Caucasians, five-year CSM rates were 41.6% after TMT versus 49.0% after EBRT and TMT independently predicted lower CSM (HR: 0.70, p < 0.001). In AAs, Hispanics and APIs, TMT did not predict CSM differences (p = 0.1, 0.2 and p = 0.06, respectively).

Conclusion

For Caucasians UCUB patients, TMT is strongly associated with significantly lower CSM. However, this observation cannot be generalized non-Caucasian subgroups, where TMT did not predict lower CSM relative to EBRT.